News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx to Announce Third Quarter 2016 Financial Results on November 7, 2016
FREMONT, Calif. , Oct. 31, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that management will host a conference call and audio webcast on Monday, November 7, 2016 , at 4:05 p.m.
View HTML
Toggle Summary Ardelyx Strengthens Executive Leadership with the Appointment of Reginald Seeto, MBBS, as Chief Operating Officer
FREMONT, Calif. , Oct. 24, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Reginald Seeto , MBBS, has joined the company in the newly created position of chief operating
View HTML
Toggle Summary Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting
Data Support Tenapanor Clinical Potential in Treating Patients with IBS-C
View HTML
Toggle Summary Ardelyx to Present at Ladenburg Thalmann 2016 Healthcare Conference
FREMONT, Calif. , Sept. 22, 2016 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Mark Kaufmann , Chief Financial Officer, will present an overview of the Company during the
View HTML
Toggle Summary Ardelyx to Present at Wedbush PacGrow Healthcare Conference
FREMONT, Calif. , Aug. 15, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Mike Raab , President and Chief Executive Officer, will present an overview of the Company during
View HTML
Toggle Summary Ardelyx Reports Second Quarter 2016 Financial Results
-- Results from the First Phase 3 trial for Tenapanor for the Treatment of Hyperphosphatemia in Patients with ESRD Expected Q1 2017 ---- Ardelyx's Proprietary Potassium Binder, RDX227675, Obtains Notification of Allowance for Composition of Matter Claims --Conference Call and Webcast Today at 4:30 p.m. ET
View HTML
Toggle Summary Ardelyx to Report Second Quarter 2016 Financial Results on August 8th, 2016
FREMONT, Calif. , Aug. 1, 2016 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report second quarter 2016 financial results after market close on Monday, August 8, 2016 .
View HTML
Toggle Summary Ardelyx Receives Notice of Allowance of Composition of Matter Patent Covering its Novel Potassium Binder RDX227675
FREMONT, Calif. , Aug. 1, 2016 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its
View HTML
Toggle Summary Ardelyx to Raise $110 Million in a Private Placement
Proceeds to Support Development of Tenapanor and RDX227675
View HTML
Toggle Summary Ardelyx Reports Progress of Development Programs
Ardelyx announces positive results from End-of-Phase 2 meeting with the FDA; the ongoing clinical trial evaluating tenapanor for the treatment of hyperphosphatemia for ESRD patients on dialysis may serve as the first of two registration trialsArdelyx announces positive pharmacodynamic trial results with convenient once daily dose of RDX227675 for hyperkalemia and subsequent development plansConference call and webcast today at 8:30am ET
View HTML